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Abstract: The purpose of this study was to determine the therapeutic effect of salvianolic 
acid b and paeonol on coronary disease. The ischemia myocardial animal model is induced 
by  administering  pituitrin  (20  μg· kg
−1)  intravenously  via  the  abdominal  vein.  A 
combination of salvianolic acid b and paeonol (CSAP) (5, 10 and 15 mg/kg BW) was 
administrated  to  experimental  rabbits.  Biochemical  indices  were  evaluated  during  six 
weeks of intervention. We found that the compound of salvianolic acid b and paeonol (5, 
10  and  15  mg/kg  BW)  can  markedly  and  dose-dependently  reduce  fibrinogen  and 
malonaldehyde  levels,  increase  the  HDL  level,  improve  blood  viscosity  and  plasma 
viscosity in rabbits. In addition, the medicine can still reduce the ratio of NO/ET and the 
contents  of  lactate  dehydrogenase  (LDH)  and  creatine  phosphokinase  (CPK)  in  a  
dose-dependent manner. This study demonstrates that compound of salvianolic acid b and 
paeonol  (5,  10  and  15  mg/kg  BW)  can  improve  the  blood  hemorrheology,  decrease 
oxidative injury and repair the function of blood vessel endothelium, and subsequently 
prevent the development of Coronary disease. 
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1. Introduction 
Coronary disease (or coronary heart disease) refers to the failure of coronary circulation to supply 
adequate  circulation  to  cardiac  muscle  and  surrounding  tissue  [1].  Disease  develops  when  a 
combination of fatty material, calcium, and scar tissue (plaque) builds up in the arteries that supply the 
heart with blood. Through these arteries, called the coronary arteries, the heart muscle (myocardium) 
gets the oxygen and other nutrients it needs to pump blood [2].  
In Chinese medicine, coronary disease belongs to “chest bi syndrome and heart pain”. There are lots 
of prescriptions for curing “chest bi syndrome” in books of traditional Chinese medicine from past 
dynasties [3]. Salvianic acid A and tea catechins have been shown to have neuroprotective actions [4–6]. 
Many experiments have demonstrated that Sal B might be able to inhibit platelet aggregation, prevent 
oxidation of low-density lipoprotein, possess strong antioxidant action in rats, and reduce the initimal 
thickness in the air-injured carotid artery [7–10]. 
A complex of salvianolic acid b and paeonol is a sustained release tablets produced in our institute. 
This medicine is mainly composed of salvianolic acid b (content > 98%) and paeonol. In this study, we 
investigate the effect of this compound of salvianolic acid b and paeonol (5, 10 and 15 mg/kg BW) on 
lipid metabolism and hemorrheology in myocardial ischemia rabbits. 
2. Materials and Method 
2.1. Reagents 
Salvianolic acid b and paeonol were extracted and combined (5:1) in our institute (Xi’an, China). 
Pituitrin injection (No. 081202) was purchased from Shanghai The First Biochemical Pharmaceutical 
Co.  Ltd  (Shanghai,  China).  Compound  salvia  pellet  (No.  20080712)  was  purchased  from  Tianjin 
TASLY Pharmaceutical Co. Ltd (Tianjin, China). Other compounds were purchased from China and 
were analytical grade. 
2.2. Animal Grouping and Treating 
Rabbits (body weight 1.0–1.5 kg) (age 4 months) were provided from the laboratory animals center 
of the fourth military medical university (Xi’an, China) and housed individually in a room suited for 
the care of experimental animals. Rabbits had free access to water and were adapted to the commercial 
pellet feed for a week, and then were separated into the following nine groups (n = 6) by randomized 
block design method: a control group; a HF (Model 1) control group; a pituitrin-treated (Model 2) 
control group; three CSAP-treated (salvianolic acid b + paeonol) groups; a SAB-treated (salvianolic 
acid b) group; a paeonol-treated group or a CSP-treated (compound salvia pellet) group. The normal 
and model 2 control groups were fed a standard chow for 12 weeks; the model 1 control group was fed Int. J. Mol. Sci. 2010, 11                       
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a high-fat diet for 12 weeks; the three CSAP-treated groups were fed with a high-fat diet and received 
the compound of salvianolic acid b and paeonol (5, 10 and 15 mg/kg BW) by gavage for 12 weeks; the 
SAB-treated  group  was  fed  a  high-fat  diet  and  received  SAB  (12.5  mg/kg  BW)  by  gavage  for  
12 weeks; the Paeonol-treated group was fed a high-fat diet and received paeonol (2.5 mg/kg BW) by 
gavage for 12 weeks; and the compound salvia pellet (CAP) group (served as a positive control) were 
fed a high-fat diet and received compound salvia pellet (20 μg·kg
−1) by gavage for 12 weeks. 
After  12  weeks  of  medicine  treatment,  all  drugs-treated  and  the  model  2  control  groups  were 
administered  pituitrin  (20  μg·kg
−1)  intravenously  via  the  abdominal  vein  to  induce  myocardial 
ischemia. Rabbits in the control  group were intravenously administered corresponding volumes of 
vehicle  solution  (saline).  Cardiac  function  was  also  recorded  at  the  same  time  by  transthoracic 
echocardiography (NEMIO SSA-550A, Toshiba, Tokyo, Japan).  
Rabbits were then anesthetized (pentobarbital) and blood was collected from the carotid artery. The 
collected blood samples were immediately centrifuged at 3000 ×  g, plasma separated, aliquoted into 
small mirocentrifuge tubes and stored at −70 °C until assayed.  
2.3. Biochemical Analysis of Serum 
Malonaldehyde  (MDA),  lactate  dehydrogenase  (LDH),  NO,  and  creatine  phosphokinase  (CPK) 
were  measured  in  a  spectrophotometer  (DU800,  Beckman)  using  commercial  kits  of  Biosino  
Bio-Technology  and  Science  Inc.  (Beijing,  China).  Total  plasma  level  of  endothelin  (ET)  was 
measured with monoclonal antibody based sandwich immunoassay (EIA) method. 
Whole-blood viscosity at shear rates from 1 to 1000 per second was measured using an automated 
capillary viscometer. Plasma viscosity was measured by performing Harkness capillary viscometry  
at 37 ° C.  
Hematocrit  was  measured  using  an  Autocrit  centrifuge  (Clay  Adams,  USA)  from  venous  
blood  collected  in  ethylenediaminetetraacetic  acid  (EDTA)  anticoagulant  and  stored  at  4–10  ° C  
until processing. 
Fibrinogen  was  measured  with  the  Swain  modification  of  the  method  of  Larsson,  Bjö rk  and 
Lundberg [11]. 
2.4. Statistical Analyses 
All results were expressed as mean ±  SD and were analyzed by SPSS for Windows, version 11.5 
(SPSS Inc, Chicago, III). A value of P less than 0.05 was considered statistically significant.  
3. Result 
3.1. Effect of Compound of Salvianolic Acid b and Paeonol Treatment on Electrocardiogram T Wave 
of Rabbits 
As shown in Table 1, the diagnostic value of electrocardiographic T Wave in the model groups was 
significantly  (p  <  0.01)  higher  than  that  in  normal  control  rats.  The  medicine-treated  groups  had 
significantly (p < 0.05, p < 0.01) lower T Wave than the model (1 and 2) groups. Compared with 
model (1 and 2) groups, there was  a significant (p < 0.05, p < 0.01)  dose-dependent decrease in  Int. J. Mol. Sci. 2010, 11                       
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T  Wave  in  CSAP-treated  groups.  The  diagnostic  value  of  electrocardiographic  T  Wave  in  the  
CSAP-treated  group  (15  mg/kg  BW)  (p  <  0.05,  p  <  0.01)  was  significantly  lower  than  those  in  
SAB-treated  and  Paeonol-treated  groups.  There  were  no  marked  changes  in  T  Wave  between  
CSAP-treated and CSP-treated rats. 
Table 1. Electrocardiogram T Wave variation of the different groups. 
Group  n  30 s  1 min  5 min  10 min  30 min 
Normal   8  020 ±  0.02  0.24 ±  0.10  0.19 ±  0.15  0.19 ±  0.22  0.03 ±  0.02 
Model 1  8  0.33 ±  0.05
ÄÄ  0.51 ±  0.16
ÄÄ  0.56 ±  0.10
ÄÄ  0.59 ±  0.20
ÄÄ  0.30 ±  0.14
ÄÄ 
Model 2  8  0.31 ±  0.06
ÄÄ  0.42 ±  0.11
ÄÄ  0.42 ±  0.10
ÄÄ  0.39 ±  0.17
ÄÄ  0.21 ±  0.12
ÄÄ 
CSAP (15 mg/kg BW)  8  0.17 ±  0.11**
  0.28 ±  0.14**  0.23 ±  0.11**  0.19 ±  0.13**  0.04 ±  0.04** 
CSAP (10 mg/kg BW)  8  0.19 ±  0.21**  0.32 ±  0.18**  0.25 ±  0.22**  0.20 ±  0.16**  0.08 ±  0.05** 
CSAP (5 mg/kg BW)  8  0.22 ±  0.18*  0.48 ±  0.46
ÄÄ  0.30 ±  0.21*  0.27 ±  0.22
Ä**  0.13 ±  0.16
Ä** 
SAB (12.5 mg/kg BW)  8  0.21 ±  0.09**
  0.38 ±  0.11**  0.27 ±  0.12**  0.22 ±  0.12**  0.10 ±  0.05** 
Paeonol (2.5 mg/kg BW)  8  0.22 ±  0.14**
  0.38 ±  0.13**  0.26 ±  0.13**  0.21 ±  0.12**  0.09 ±  0.03** 
CSP (20 μg·kg
−1)  8  0.16 ±  0.14**  0.24 ±  0.18**  0.23 ±  0.31**  0.27 ±  0.33**  0.01 ±  0.04** 
Ä: P < 0.05, 
ÄÄ: P < 0.01, compared with normal group; *: P < 0.05, **: P < 0.01, compared with model group. 
3.2. Effect of Compound of Salvianolic Acid b and Paeonol Treatment on Hemorrheology in Rabbits 
As shown in Table 2, the whole-blood viscosity, plasma viscosity, hematocrit and fibrinogen level 
in  the  model  (1  and  2)  groups  was  significantly  higher  than  that  in  normal  control  rats 
(p < 0.05; p < 0.01). The compound of salvianolic acid b and paeonol treatment (10 and 15 mg/kg BW) 
significantly  (p < 0.05; P < 0.01)  and  dose  dependently  prevented  this  increase  in  whole-blood 
viscosity,  plasma  viscosity,  hematocrit  and  fibrinogen  level  in  CSAP-treated  groups  compared  to 
model (1 and 2) groups. Whole-blood viscosity, plasma viscosity, hematocrit and fibrinogen level in 
the CSAP-treated group (15 mg/kg BW) (p < 0.05, p < 0.01) was significantly lower than those in the 
SAB-treated  and  Paeonol-treated  groups.  Likewise,  administering  20  μg·kg
−1  of  Compound  salvia 
pellet in CSP-treated rats significantly reduced the whole-blood viscosity, plasma viscosity, hematocrit 
and fibrinogen level (p < 0.01). 
Table 2. Variations in hemorrheology of the different groups. 
Group  
Whole-blood Viscosity (mpa· s) 
Plasma Viscosity 
(mpa· s) 
Hematocrit  
(%) 
Fibrinogen 
(g/L) 
Low Shear 
Rate 
High Shear 
Rate 
Normal   7.36 ±  1.09  3.36 ±  0.21  1.12 ±  0.04  42.56 ±  2.82  1.68 ±  1.22 
Model 1  13.12 ±  2.26
ÄÄ  4.50 ±  0.41
ÄÄ  1.37 ±  0.15
ÄÄ  46.88 ±  3.78
Ä  3.81 ±  1.56
Ä 
Model 2  10.34 ±  2.04
ÄÄ  3.91 ±  0.39
ÄÄ  1.23 ±  0.14
ÄÄ  44.94 ±  3.47
Ä  2.98 ±  1.48
Ä 
CSAP (15 mg/kg BW)  9.73 ±  0.45**  3.97 ±  0.55**  1.19 ±  0.07**  40.12 ±  7.03**  2.09 ±  0.63** 
CSAP (10 mg/kg BW)  9.89 ±  0.98**  4.03 ±  0.18**  1.19 ±  0.05**  41.08 ±  5.72**  2.59 ±  0.55** 
CSAP (5 mg/kg BW)  10.12 ±  1.21*
ÄÄ  4.15 ±  0.27*  1.21 ±  0.09**  45.37 ±  6.21  2.83 ±  1.06* 
SAB (12.5 mg/kg BW)  10.01 ±  0.89**  4.06 ±  0.61**  1.20 ±  0.08**  42.73 ±  8.11**  2.68 ±  0.71** 
Paeonol (2.5 mg/kg BW)  9.95 ±  0.69**  3.99± 0.42**  1.19 ±  0.06**  43.37 ±  8.09**  2.72 ±  0.84* 
CSP (20 μg·kg
−1)  9.78 ±  0.53**  3.92 ±  0.67**  1.17 ±  0.06**  41.09 ±  7.13*  2.11 ±  0.66** 
Ä: P < 0.05, 
ÄÄ: P < 0.01, compared with normal group; *: P < 0.05, **: P < 0.01, compared with model group. Int. J. Mol. Sci. 2010, 11                       
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3.3. Effect of Compound of Salvianolic Acid b and Paeonol Treatment on Blood MDA, NO, ET, 
NO/ET, LDH, and CPK 
As shown in Table 3 and 4, blood MDA, NO, LDH, CPK levels and NO/ET in model (1 and 2) 
groups were significantly (p < 0.05; p < 0.01) higher than those in normal control rats. Compared with 
model (1 and 2) controls, administration of compound of salvianolic acid b and paeonol at 5, 10 and 
20 mg/kg  bw  significantly  decreased  blood  MDA,  NO,  ET,  LDH,  CPK  levels  and  NO/ET  in  
CSAP-treated  rats.  Blood  MDA,  NO,  LDH,  CPK  levels  and  NO/ET  in  the  CSAP-treated  group  
(15  mg/kg  BW)  (p < 0.05, p < 0.01)  was  significantly  lower  than  those  in  SAB-treated  and  
Paeonol-treated groups. As shown in Table 3 and 4, administering 20 μg·kg
−1 of Compound salvia 
pellet, used as a positive control, in CSP-treated rats significantly decreased blood MDA, NO, ET, 
LDH, CPK levels and NO/ET. 
Table 3. Effect of compound of salvianolic acid b and paeonol treatment on blood MDA, 
NO, ET levels and NO/ET in the different groups of rabbits. 
Group  n  MDA (nmol· mL
−1)  NO (μmol·mL
−1)  ET (pg· mL
−1)  NO/ET 
Normal   8  2.25 ±  0.42  54.82 ±  17.59  335.07 ±  48.21  0.16 ±  0.05 
Model 1  8  3.18 ±  0.53
ÄÄ  122.93 ±  23.15
ÄÄ  385.77 ±  56.21  0.32 ±  0.05
ÄÄ 
Model 2  8  2.62 ±  0.49
Ä  107.68 ±  20.12
ÄÄ  378.32 ±  49.87  0.29 ±  0.05
ÄÄ 
CSAP (15 mg/kg BW)  8  1.95 ±  0.23*  62.68 ±  11.12**  263.45 ±  26.31
ÄÄ  0.24 ±  0.05* 
CSAP (10 mg/kg BW)  8  2.42 ±  0.48*  81.08 ±  12.10
ÄÄ**  317.21 ±  68.12  0.26 ±  0.08* 
CSAP (5 mg/kg BW)  8  2.75 ±  0.62
Ä*  104.23 ±  13.42
ÄÄ*  365.41 ±  75.24  0.29 ±  0.10 
SAB (12.5 mg/kg BW)  8  2.25 ±  0.21*  88.53 ±  18.04
ÄÄ**  321.37 ±  59.51  0.27 ±  0.06* 
Paeonol (2.5 mg/kg BW)  8  2.33 ±  0.32*  83.08 ±  15.39
ÄÄ**  336.72 ±  72.48  0.26 ±  0.05* 
CSP (20 μg·kg
−1)  8  1.93 ±  0.41*  60.45 ±  15.12**  258.87 ±  65.12**  0.24 ±  0.07* 
Ä : P < 0.05, 
ÄÄ : P < 0.01, compared with normal group; *: P < 0.05, **: P < 0.01, compared with model group. 
Table 4. Effect of compound of salvianolic acid b and paeonol treatment on blood LDH 
and CPK in the different groups of rabbits. 
Group   n  LDH  CPK 
Normal   8  532 ±  125  737 ±  258 
Model 1  8  779 ±  318
Ä  1862 ±  437
ÄÄ 
Model 2  8  713 ±  285
Ä  1659 ±  401
ÄÄ 
CSAP (15 mg/kg BW)  8  564 ±  151*  790 ±  593** 
CSAP (10 mg/kg BW)  8  688 ±  171  1022 ±  469* 
CSAP (5 mg/kg BW)  8  763 ±  140  1715 ±  586 
SAB (12.5 mg/kg BW)  8  698±1 73  1274± 638* 
Paeonol (2.5 mg/kg BW)  8  709±1 83  1308±5 16* 
CSP (20 μg· kg
−1)  8  551 ±  124  803 ±  498** 
Ä: P < 0.05, 
ÄÄ: P < 0.01, compared with normal group; *: P < 0.05, **: P < 0.01, compared with model group. Int. J. Mol. Sci. 2010, 11                       
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4. Discussion 
Pituitrin  is  hormones  released  from  the  posterior  lobe  of  the  pituitary,  including  vasopressin 
(antidiuretic hormone) and oxytocin. They are formed in the neuronal cells of the hypothalamic nuclei 
and  stored  in  nerve  cell  endings  in  the  posterior  pituitary  (neurohypophysis)  [12].  In  this  study, 
intravenous administration of 20 μg·kg
−1 pituitrin caused bradycardia, decreased cardiac output and 
induced  acute  myocardial  ischemia.  Cmpound  of  salvianolic  acid  b  and  paeonol  treatment  could 
alleviate  pituitrin-induced  acute  myocardial  ischemia  in  rabbits.  A  previous  study  showed  
that  administration  of  salvianolic  acid  A  for  a  period  of  eight  days  significantly  attenuated  
isoproterenol-induced  cardiac  dysfunction  and  myocardial  injury  and  improved  mitochondrial 
respiratory function [13]. This was in agreement with the result of our study. 
Hemorheological parameters are primary risk factors in coronary heart disease (CHD). Clinical 
experiments  proved  that  whole  blood  viscosity  and  plasma  viscosity  were  higher  in  patients  with 
coronary heart disease [14]. In the present experiment, compound of salvianolic acid b and paeonol 
treatment  could  significantly  reduce  whole  blood  viscosity  and  plasma  viscosity  and  improve 
hemorheology in rabbits.  
Free radical-mediated injury has been proposed to be one of the major components involved in the 
pathophysiological alterations observed during ischemia and reperfusion. In the heart, reactive oxygen 
intermediates  such  as  the  superoxide  anion  and  the  hydroxyl  radical,  which  are  formed  during 
reperfusion  or  reoxygenation  of  the  ischemic  tissue,  may  be  responsible  for  the  induction  of 
electrophysiological  and  biochemical  disturbances  [15–18].  These  alterations  can  lead  to  the 
development  of  reperfusion  arrhythmia,  myocardial  stunning,  or  necrosis  acceleration  [19].  Lipid 
peroxidation has been hypothesized to be a major mechanism of free radicals cell damage. It may alter 
intrinsic membrane properties, due to physicochemical changes of oxidized lipids, or secondary to 
crosslinking and polymerization of membrane components affected by MDA. Lipid peroxidation may 
also  indirectly  contribute  to  other  deleterious  effects  of  ischemia/reperfusion,  because  it  enhances 
phospholipid  susceptibility  to  degradation  by  phospholipases  and  increases  membrane  calcium 
permeability [20–22]. Tian et al. [23] showed that SMND-309 (a new derivate of salvianolic acid B) 
decreased  neurological  deficit  scores,  reduced  the  number  of  dead  hippocampal  neuronal  cells  in 
accordance with its depression on mitochondria swelling degree, reactive oxygen species production, 
improvements  on  mitochondria  swelling,  energy  metabolism,  membrane  potential  level  and 
mitochondrial respiratory chain complex activities. In this study, compound of salvianolic acid b and 
paeonol  treatment  could  decrease  plasma  MDA  level,  indicating  that  the  medicine  may  reduce 
oxidative injury in myocardial ischemia rabbits. 
In addition, excessive nitric oxide (NO) has also been implicated in the induction of myocardial 
dysfunction, apoptosis, and mitochondrial respiratory chain inhibition. As the largest reservoir for O2 
and NO in the body, hemoglobin acts as an important mediator of the nitroso-redox balance [24, 25]. 
Danshensu pretreatment can effectively inhibit I/R arrhythmia, ventricular arrhythmia incidence rate, 
onset time and duration time of VT and VT were lower than in hypertrophy groups; Danshensu were 
effective in preventing hypertrophy progression in rats; serum NO content and eNOS activity were 
significantly enhanced toward normal range [26]. In this study, a  compound of salvianolic acid b  Int. J. Mol. Sci. 2010, 11                       
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and  paeonol  treatment  reduced  blood  NO  level,  and  consequently  prevented  angiospasm  and  
platelet aggregation.  
Endothelin (ET) is an endothelium-derived vasoactive mediator that was discovered in 1988. ET 
has multiple biologic actions, it contracts vascular and nonvascular smooth muscles in vitro, produces 
a sustained and long-lasting pressor response in vivo and exerts a positive inotropic effect on the 
cardiac  muscle  [27].  Increased  plasma  ET  concentrations  have  been  reported  in  a  variety  of 
cardiovascular disorders. ET is  supposed to  play  a role in  the pathophysiology of acute coronary 
syndromes. Serum CPK and LHD activities may reflect myocardiac tissue injury.  
Our study showed that compound of salvianolic acid b and paeonol treatment could decrease serum 
ET level, CPK and LHD activities in myocardial ischemia rabbits. This indicated that this medicine 
may alleviate coronary artery spasm and protect myocardial cell membrane. Moreover, compound of 
salvianolic acid b and paeonol treatment had a synergistic part in reducing myocardial injury induced 
by pituitrin. 
5. Conclusion 
In summary, the present study demonstrates for the first time that compound of salvianolic acid b 
and paeonol can prevent angiospasm and platelet aggregation, improve myocardial cells function and 
blood rheology, increase coronary blood flow and reduce oxidative injury. These results suggest that 
the cardiovascular benefits of compound of salvianolic acid b and paeonol be explained, at least in 
part,  by  improving  blood  hemorheology,  decreasing  serum  ET  and  MDA  level,  CPK  and  LHD 
activities in myocardial cells.  
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